Evidence map›Paper›PMID 40579411›Full record

ArticleScientific reports2025

Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients.

Eman M F Barakat, Mohamed Kohla, Hossam Dabees, Hend Ibrahim Shousha, Ehab F Moustafa, Mohamed El-Kassas, Mona Shoukry Aziz, Eman Elkhateeb, Ashraf Omar Abdelaziz, Mohamed Omar Abdelmalek and 31 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Eman M F BarakatHepatoma Group, Tropical Medicine Department, Ain Shams University, Cairo, Egypt.
Mohamed KohlaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Hossam DabeesNational Medical Institute of Damnhour, Damnhour, Egypt.
Hend Ibrahim ShoushaEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt. hendshousha@kasralainy.edu.eg.ORCID http://orcid.org/0000-0002-0928-4738
Ehab F MoustafaDepartment of Tropical Medicine and Gastroenterology, Assuit University, Assuit, Egypt.
Mohamed El-KassasEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Mona Shoukry AzizNational Medical Institute of Damnhour, Damnhour, Egypt.
Eman ElkhateebHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Ashraf Omar AbdelazizEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Mohamed Omar AbdelmalekDepartment of Tropical Medicine and Gastroenterology, Assuit University, Assuit, Egypt.
Aly AzmyDepartment of Medical Oncology and Nuclear Medicine, Ain Shams University, Cairo, Egypt.
Ahmed TawheedEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Walaa Mosaad AboganobNational Medical Institute of Damnhour, Damnhour, Egypt.
Hossam TahaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Rania LithyEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Ahmed RadwanDepartment of Tropical Medicine and Gastroenterology, Assuit University, Assuit, Egypt.
Dalia GhorabaHepatoma Group, Tropical Medicine Department, Ain Shams University, Cairo, Egypt.
Hamdy SayedEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Anwar NassiefNational Medical Institute of Damnhour, Damnhour, Egypt.
Mostafa ElhelbawyHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Mohamed Mahmoud NabeelEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Mohamed A MedhatDepartment of Tropical Medicine and Gastroenterology, Assuit University, Assuit, Egypt.
Safaa Ragab AskarHepatoma Group, Tropical Medicine Department, Ain Shams University, Cairo, Egypt.
Eman MarwanEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Eman RewishaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Tamer ElbazEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Sayed Hassan AhmedDiagnostic and Interventional Radiology, Faculty of Medicine, Assuit University, Assuit, Egypt.
Nevien Fouad ElfoulyNational Center for Radiation Research and Technology Egyptian Atomic Energy Authority, Cairo, Egypt.
Nermeen AbdeenTropical Medicine Department, Alexandria University, Alexandria, Egypt.
Ahmed Hosni AbdelmaksoudDiagnostic and Interventional Radiology Department, Cairo University, Cairo, Egypt.
Asmaa A AbdeltawabOncology Department, Faculty of Medicine, Assuit University, Assuit, Egypt.
Mostafa Abd Alfattah ShamkhHepatoma Group, Tropical Medicine Department, Ain Shams University, Cairo, Egypt.
Ahmed RamadanEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Yasser Arafat AbdelrazekHepatoma Group, Tropical Medicine Department, Ain Shams University, Cairo, Egypt.
Mohamed BassamEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Sayed Ahmed SayedHepatoma Group, Tropical Medicine Department, Ain Shams University, Cairo, Egypt.
Rasha Salah HusseinDiagnostic and Interventional Radiology Department, Ain Shams University, Cairo, Egypt.
Ammar AlrajhiEndemic Medicine and Hepato-Gastroenterology Department, Cairo University, Cairo, Egypt.
Allam Elsayed AllamDiagnostic and Interventional Radiology Department, Ain Shams University, Cairo, Egypt.
Omnia A SeyamDiagnostic and Interventional Radiology Department, Ain Shams University, Cairo, Egypt.
Mohamed SaidNational Medical Institute of Damnhour, Damnhour, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the characteristics and survival of patients with sorafenib-treated HCC and impact of underlying etiology on outcomes. This retrospective multicenter study recruited patients with sorafenib-treated advanced HCC (12/2016 to 4/2023) till death or the study end (2/2024). Time to progression (TTP) and overall survival (OS) were recorded. We evaluated; Clinico-laboratory and imaging predictors of OS, The impact of underlying etiology on tumor variables, outcomes and tolerance for sorafenib > 6 months. This study included 706 patients. Median duration of Sorafenib therapy was 240.00 (90.00-360.00) days. Median OS was 314.00(146.00-601.00) days. Median TTP was 180.00(90.00-330.00) days. COX regression revealed that the independent factors of mortality were baseline AST, Tumor size, hepatic vein thrombosis (HVT), development of jaundice and shifting to Regorafenib. Advanced HCCs were more common on top of non-cirrhotic non-viral and HBV-related liver disease. Adverse events, TTP and tumor response didn't differ with the underlying etiology. Median OS was lower in non-viral-related HCC than HCV-related HCC (218.00 versus 326.50 days, P-value = 0.048). Patients who continued sorafenib > 6 months had lower AFP, HVT, adverse effects and better tumor response after 3 months. OS is lower in non-viral Sorafenib-treated HCC compared with viral-related HCC and Sorafenib was well-tolerated among different HCC etiologies.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsProtein Kinase InhibitorsSorafenibAdultAgedFemaleHumansMaleMiddle AgedPhenylurea CompoundsRetrospective StudiesTreatment OutcomeTyrosine Kinase InhibitorsAntineoplastic AgentsPhenylurea CompoundsProtein Kinase InhibitorsSorafenibTyrosine Kinase InhibitorsHepatitisHepatocellular carcinomaRegorafenibSorafenibSurvival

Identifiers

PMID40579411
PMCPMC12205039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.